The Mechanism and Some Controversies of SGLT2 Inhibitor Protects the Cardiovascular System

  • Shuo Zhang Xiamen University
DOI: https://doi.org/10.18686/aem.v11i4.341
Keywords: Sglt2 Inhibitor, Cardiovascular Event, Heart Failure, Metabolization

Abstract

SGLT2 inhibitor, a kind of hypoglycemic drug, whose mechanism is to suppress glucose reabsorption in proximal renal tubules in the kidney to promote the excretion of glucose, has been demonstrated to have a positive effect on our cardiovascular system and reduce the risk of suffering from cardiovascular events. In this review, we will focus on four aspects to elaborate on its mechanism. First: diuresis and electrolytes, second: blood pressure, hormone, and nerve, third: regulating lipid metabolism, and the last: the direct effect on cardiomyocytes. This paper presents some puzzles of different mechanisms, aiming for waiting to be answered in later research.

References

[1] Boorsma EM, Beusekamp JC, ter Maaten JM, et al. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. European Journal of Heart Failure. 2021; 23(1):68.

[2] Mordi NA, Mordi IR, Singh JS, Mccrimmon RJ, Struthers AD, Lang CC. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial. Circulation. 2020; 142(18):1713.

[3] Van Bommel EJM, Geurts F, Muskiet MHA, et al. SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes. Clin Sci (Lond). 2020;134(23):3107-3118.

[4] De Jong MA, Petrykiv SI, Laverman GD, et al. Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis. Clin J Am Soc Nephrol. 2019; 14(1): 66-73.

[5] Zanchi A, Burnier M, Muller ME, et al. Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo‐Controlled Trial. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. 2020;9(13).

[6] Thiele K, Rau M, Hartmann NUK, et al. Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study. Diabetes Obes Metab. 2021; 23(12):2814-2818.

[7] Shimizu W, Kubota Y, Hoshika Y, et al. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol. 2020;19(1).

[8] Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial. Diabetes, Obesity and Metabolism. 2021;23(6):1426-1430.

[9] Nassif ME, Qintar M, Windsor SL, et al. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial. Circulation. 2021;143(17):1673-1686.

[10] Kullmann S, Hummel J, Wagner R, et al. Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial. Diabetes Care. 2022;45(2):398-406.

[11] Hayashi T, Fukui T, Nakanishi N, et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017;16(1).

[12] De Koning MSLY, Westenbrink BD, Assa S, et al. Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2021;78(14):1421-1432.

[13] Carnicelli AP, Sun JL, Alhanti B, et al. Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX. Am J Med. 2020;133(12):e716-e721.

[14] Hiruma S, Shigiyama F, Hisatake S, et al. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovasc Diabetol. 2021;20(1).

[15] Lauritsen KM, Nielsen BRR, Tolbod LP, et al. SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial. Diabetes. 2021;70(3):800-808.
Published
2023-03-02
Issue
Vol 11, No 4 (2022)
Section
Original Research Article

Copyright (c) 2023 Shuo Zhang

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.